Skip to main content

Tiludronate Side Effects

Medically reviewed by Last updated on Jul 15, 2022.

Applies to tiludronate: oral tablet


The most frequently occurring adverse reactions reported were: Diarrhea (9.3%), nausea (9.3%), and dyspepsia (5.3%).[Ref]


Common (1% to 10%): Hypertension, flushing[Ref]


Common (1% to 10%): Rash, skin disorder, pruritus, increased sweating[Ref]


Common (1% to 10%): Hyperparathyroidism[Ref]


Common (1% to 10%): Diarrhea, nausea, dyspepsia, vomiting, flatulence, tooth disorder, abdominal pain, constipation, dry mouth gastritis[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Common (1% to 10%): Vitamin D deficiency, anorexia[Ref]


Bone, joint, and/or muscle pain, rarely severe and/or incapacitating have been reported.[Ref]

Common (1% to 10%): Arthralgia, back pain, arthrosis, fracture pathological, skeletal pain

Postmarketing reports: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, including this drug[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, paresthesia, vertigo, involuntary muscle contractions, somnolence, nervousness[Ref]


Common (1% to 10%): Cataract, conjunctivitis, glaucoma[Ref]


Common (1% to 10%): Pain, accidental injury, influenza like symptoms, chest pain, peripheral edema, infection, asthenia, syncope, fatigue[Ref]


Common (1% to 10%): Insomnia, anxiety[Ref]


Common (1% to 10%): Rhinitis, sinusitis, upper respiratory tract infection, coughing, pharyngitis, bronchitis[Ref]


Rare (less than 0.1%): Stevens-Johnson syndrome[Ref]


1. "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.

2. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

4. Cerner Multum, Inc. "Australian Product Information." O 0

5. Roux C, Listrat V, Villette B, Lessana-Leibowitch M, Ethgen D, Pelissier C, Dougados M, Amor B "Long-lasting dermatological lesions after tiludronate therapy." Calcif Tissue Int 50 (1992): 378-80

6. Reginster JY, Lecart MP, Deroisy R, Ethgen D, Zegels B, Franchimont P "Paget's disease of bone treated with a five day course of oral tiludronate." Ann Rheum Dis 52 (1993): 54-7

7. Fraser WD, Stamp TC, Creek RA, Sawyer JP, Picot C "A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone." Postgrad Med J 73 (1997): 496-502

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.